Cargando…

Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy

Specific cellular immunotherapy for cancer requires efficient generation and expansion of cytotoxic T lymphocytes (CTLs) that recognize tumor-associated antigens. However, it is difficult to isolate and expand functionally active T-cells ex vivo. In this study, we investigated the efficacy of a new...

Descripción completa

Detalles Bibliográficos
Autores principales:	YOSHIKAWA, TOSHIAKI, TAKAHARA, MASASHI, TOMIYAMA, MAI, NIEDA, MIE, MAEKAWA, RYUJI, NAKATSURA, TETSUYA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203331/ https://www.ncbi.nlm.nih.gov/pubmed/25189159 http://dx.doi.org/10.3892/ijo.2014.2634

Ejemplares similares

Zoledronate-pulsed dendritic cell-based anticancer vaccines
por: Kamigaki, Takashi, et al.
Publicado: (2013)

Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug
por: Tanaka, Yoshimasa, et al.
Publicado: (2018)

Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells
por: Wilhelm, Martin, et al.
Publicado: (2014)

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
por: SUGAI, SHIORI, et al.
Publicado: (2016)

Possibility of γδ T cell immunotherapy for HTLV-1-infected individuals
por: Sato, Tomoo, et al.
Publicado: (2011)

Peptide intra-tumor injection for cancer immunotherapy: Enhancement of tumor cell antigenicity is a novel and attractive strategy
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates
por: Wang, Shengdong, et al.
Publicado: (2018)

Characterization of Donor Variability for γδ T Cell ex vivo Expansion and Development of an Allogeneic γδ T Cell Immunotherapy
por: Burnham, Rebecca E., et al.
Publicado: (2020)

Synergy between liposomal zoledronic acid and γδ T-cells in the treatment of epithelial ovarian cancer
por: Pereira, Ana Catarina Parente, et al.
Publicado: (2013)

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes
por: SAWADA, YU, et al.
Publicado: (2014)

Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial
por: Hirooka, Yoshiki, et al.
Publicado: (2017)

Development of adoptive immunotherapy with KK‐LC‐1‐specific TCR‐transduced γδT cells against lung cancer cells
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes
por: Akazawa, Yu, et al.
Publicado: (2019)

Dysregulated CD25 and Cytokine Expression by γδ T Cells of Systemic Sclerosis Patients Stimulated With Cardiolipin and Zoledronate
por: Migalovich Sheikhet, Helena, et al.
Publicado: (2018)

Next-Generation Cancer Immunotherapy Targeting Glypican-3
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Optimized protocols for γδ T cell expansion and lentiviral transduction
por: Wang, Rui-Ning, et al.
Publicado: (2019)

Identification of an H2-K(b) or H2-D(b) restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide
por: IWAMA, TATSUAKI, et al.
Publicado: (2013)

Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2(+) γδ T cell cytotoxicity in a perforin-dependent manner
por: Fowler, Daniel W., et al.
Publicado: (2017)

The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy
por: Legut, Mateusz, et al.
Publicado: (2015)

Exploring the Utility of NK Cells in COVID-19
por: Deng, Xuewen, et al.
Publicado: (2022)

Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP
por: Roelofs, Anke J, et al.
Publicado: (2009)

Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy
por: Nobuoka, Daisuke, et al.
Publicado: (2012)

Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study
por: Yamaguchi, Yoshiyuki, et al.
Publicado: (2020)

Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study
por: Yamaguchi, Yoshiyuki, et al.
Publicado: (2022)

Re-generation of cytotoxic γδT cells with distinctive signatures from human γδT-derived iPSCs
por: Murai, Nobuyuki, et al.
Publicado: (2023)

Immunosurveillance of Cancer and Viral Infections with Regard to Alterations of Human NK Cells Originating from Lifestyle and Aging
por: Deng, Xuewen, et al.
Publicado: (2021)

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
por: TADA, YOSHITAKA, et al.
Publicado: ( 201)

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2014)

Dendritic cells cross‐talk with tumour antigen‐specific CD8(+) T cells, Vγ9γδT cells and Vα24NKT cells in patients with glioblastoma multiforme and in healthy donors
por: Eiraku, Y., et al.
Publicado: (2018)

γδ T Cells and Their Potential for Immunotherapy
por: Wu, Yan-Ling, et al.
Publicado: (2014)

γδ T cells in cancer immunotherapy
por: Zou, Chang, et al.
Publicado: (2016)

In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study
por: Pressey, Joseph G., et al.
Publicado: (2016)

Cancer immunotherapy‐targeted glypican‐3 or neoantigens
por: Shimizu, Yasuhiro, et al.
Publicado: (2018)

Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy
por: Oberg, Hans-Heinrich, et al.
Publicado: (2014)

TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells
por: Tawfik, Doaa, et al.
Publicado: (2019)

Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation
por: Nada, Mohanad H., et al.
Publicado: (2017)

Peptide vaccines for hepatocellular carcinoma
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer
por: Akazawa, Yu, et al.
Publicado: (2020)

γδ T Cell Immunotherapy—A Review
por: Kobayashi, Hirohito, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6rv0uu9pcj2aeqri54hvvb2rus